PEPTIDE CORTEXThe library
← The library

KLOW

Blend (KPV + BPC-157 + TB-500 + GHK-Cu)Healing/Recovery
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeRecovery / inflammation blend (KPV + BPC-157 + TB-500 + GHK-Cu)
MechanismPre-mixed blend of KPV, BPC-157, TB-500 and GHK-Cu (Copper peptide) in one vial (commonly 80 mg). Each component is a separate research compound; the combination itself has not been studied as a product.
EffectsWhat the components are individually studied for: KPV — Anti-inflammatory / GI; BPC-157 — Healing / Recovery; TB-500 — Healing / Recovery; GHK-Cu (Copper peptide) — Skin / Hair. Read each component’s own entry for its evidence.
DosingNo human dose established.
Bottom lineA vendor-defined combination: no trial has tested the blend, and its evidence is no stronger than its weakest component.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOnce daily
StartingWeeks 1-2: about 1.25 mg GHK-Cu + about 250 mcg each of KPV, BPC-157, TB-500
EscalationWeeks 3-4: about 2.5 mg GHK-Cu + about 500 mcg each of the other three. Weeks 5-8: about 3.75 mg GHK-Cu + about 750 mcg each.
TargetTitrated as above ("representative titration phases")
Cycle4-6 weeks on, 2-4 weeks off; copper accumulation from GHK-Cu drives the off period

Commonly 80 mg = GHK-Cu 50 + 10 each of KPV, BPC-157, TB-500. At the week 5-8 step the GHK-Cu component exceeds the standalone GHK-Cu community ceiling of 2 mg/day. No trial has tested the blend.

Batches on filenone

No tested batches on file.

Read with4
Cautions & interactions

Research-grade blend; not FDA-approved. It carries the cautions of every component — read each one’s entry. Injection-site reactions possible; discuss with a clinician, especially if on anticoagulants or immunosuppressants.

No interaction data for the blend. Each component’s interaction notes apply; avoid combining multiple research compounds without a clinician.

CV 1 of 5 — No cardiovascular outcomes data for the blend; see each component.